Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (5549)	9/1/1998 12:40:00 PM
From: Rocketman	Read Replies (1) \| Respond to of 9719

Selling what to create margin room? Ain't no way we get back to buying power without selling the farm. I'm set to ride it out. Right this moment down $3700 on the day, we are at 32% and still not in a margin call. I hate to sell out at the bottom like this when we still have a bit of room and would rather wait until we are forced to do something, like 5 days after we are in a call. Hang tough V1, it is two motorcycles coming down the road and they'll go around us..... Uh I don't think it is a Motorhome bearing down on us.....Stay tuned for the exciting answer. Besides it is only paper money, the real stuff has already been eroded away. Debt is the answer, there is always bankrutpcy... ya know it must feel good to screw the banks for a change. Remember in the US, you are measured not by your net worth, but by the size of your debt load (just like the government). If you are worth $1000, you carry $10K in debt if you are worth a million you carry $10 million in debt, etc, etc, etc..... Rman

To: Vector1 who wrote (5549)	9/1/1998 4:46:00 PM
From: Mel Kaplan	Read Replies (1) \| Respond to of 9719

V!, I too am struck that the FDA was concerned by quality control of a complex influenza virus vaccine, composed of a mixture of heat-killed and attenuated live viral strains and produced in the UK ,supplied in bulk to AVIR in CA for assembly and packaging. Avir has supported the efficacy of the vaccine in terms of antibody response and clinical infection and protection from ear infection in children. In the original report, it was noted that a small number of patients developed fever after the nasal instillation, which was transient but unexplained, and dismissed. The FDA did not apparently cite this. It did not accept for filing the British papers on the quality of the bulk product. Rman may be right in tha whole matter can be reconciled by responses of AVIR, but the FDA is doing its job. Mel